KALV - KalVista Pharmaceuticals up 16% prices $160M offering
2024-02-15 06:43:24 ET
More on KalVista Pharmaceticals
- KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
- KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement
- Two biotech/pharma stocks to watch - STTK, KALV
- KalVista jumps as rare disease therapy hits main goal in Phase 3 trial